February 7, 2019 – researchers from Johns Hopkins said the active ingredient in hallucinogenic mushrooms – psilocybin – has low abuse potential, and could reduce psychological distress and opioid abuse potential they would recommend reclassifying psilocybin from a schedule I drug – one that has no known medical potential – to a schedule IV drug – one that has low potential for abuse and dependence.
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…